SB-480848. GlaxoSmithKline.

Abstract

SB-480848 is a reversible lipoprotein-associated phospholipase A2 inhibitor under development by GlaxoSmithKline for the potential treatment of atherosclerosis. Phase II trials with SB-480848 are currently underway.

• Authors: David P Rotella
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 5 Issue 3 Pg. 348-51 (Mar 2004) ISSN: 1472-4472 [Print] England
• PMID: 15083604 (Publication Type: Journal Article, Review)

Chemical References

• Enzyme Inhibitors
• Pyrimidinones
• Phospholipases A
• Phospholipases A2
• darapladib

Topics

• Animals
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Coronary Artery Disease (drug therapy)
• Enzyme Inhibitors (chemical synthesis, chemistry, pharmacokinetics)
• Humans
• Phospholipases A (antagonists & inhibitors)
• Phospholipases A2
• Pyrimidinones (chemical synthesis, chemistry, pharmacokinetics)